Primary Intracerebral HemorrhageNCT06836141
Biomarkers for Cognitive Decline in Intracerebral Hemorrhage
An observational study of Primary Intracerebral Hemorrhage, run by Rush University Medical Center at 1 site in United States.
Trial summary
The goal of this clinical trial is to see if silent brain infarcts (SBIs), or stroke-like symptoms detectable during brain imaging, are a possible contributor to cognitive decline for patients diagnosed with spontaneous intracerebral hemorrhage (sICH), or blood clot in the brain. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Primary Intracerebral Hemorrhage
- What is being tested?
- MRI, Blood Draw and Cognitive Test
- How many people
- 118 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Aug 2025to 1 Aug 2029
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients admitted to Rush University Medical Center with an intracerebral hemorrhage.
Who may be able to join
- Primary Intracerebral Hemorrhage
- Age ≥ 18 and < 80 years
Who cannot join
- Pre-existing dementia
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Rajeev Garg, MD contact
United States1 site, 1 recruiting
- Recruiting
Rush University Medical Center
Chicago, Illinois, 60614
Rajeev Garg, MD, Rajeev_Garg@rush.edu
Amanda Sremac, BS, 312-942-0593, Amanda_C_Sremac@rush.edu
About this study
Official title: Silent Brain Infarcts in Spontaneous Intracerebral Hemorrhage as a Prognostic Biomarker for Vascular Contributions to Cognitive Impairment and Dementia (VCID)
The goal of this clinical trial is to see if silent brain infarcts (SBIs), or stroke-like symptoms detectable during brain imaging, are a possible contributor to cognitive decline for patients diagnosed with spontaneous intracerebral hemorrhage (sICH), or blood clot in the brain. The main questions it aims to answer are
- if SBIs in sICH are associated with a lower cognitive level and more rapid cognitive decline
- if SBIs in sICH are associated with certain findings on brain imaging
- if SBIs in sICH are associated with higher inflammation measured by certain blood tests
Read more
Participants will undergo
- cognitive testing during hospitalization, and at 3, 6 and 12 months after the sICH
- Magnetic Resonance Imaging (MRI) of the brain during hospitalization and 12 months after the sICH
- blood draws during hospitalization and at 3, 6 and 12 months after the sICH
Read the detailed description
This proposal's objective is to establish SBIs (silent brain infarct) as an early, pathophysiologically plausible neuroimaging biomarker for VCID (vascular contributions to cognitive impairment and dementia) in sICH (spontaneous intracerebral hemorrhage) patients. To attain the overall objective, we will recruit a cohort of 118 sICH participants over 3 years and longitudinally measure cognitive function, WMH volumetric progression, and serum suPAR levels. Aim #1: To test the hypothesis that SBIs in sICH are associated with a lower cognitive level and more rapid cognitive decline. Approach: In sICH patients with and without SBIs, we will compare global cognition (primary analysis) and multiple cognitive domains (secondary analysis) at hospitalization, and at 3 months, 6 months, and 12 months after discharge using a comprehensive cognitive battery. Aim #2: To test the hypothesis that SBIs in sICH are associated with more rapid WMH (white matter hyperintensities) progression as measured by serial MRI (magnetic resonance imaging). Approach: In sICH patients with and without SBIs, we will compare the absolute volumetric change in WMH using a novel imaging analysis algorithm on serial 3-Tesla brain MRI at hospitalization and at 12 months after discharge. Aim #3: To test the hypothesis that SBIs in sICH are associated with higher chronic systemic inflammation as measured by serum suPAR. Approach: In sICH patients with and without SBIs, we will compare serum levels of suPAR at hospitalization, and at 3 months, 6 months, and 12 months after discharge.
This study will be a prospective longitudinal study of sICH patients comparing those with and without SBIs. All patients with primary sICH are admitted to Rush University Medical Center's (RUMC) Neurosciences Intensive Care Unit and managed by a multi-disciplinary team of neurologists and neurosurgeons according to a standardized protocol based on current guidelines. Primary sICH will be defined as either hypertensive or related to cerebral amyloid angiopathy as diagnosed using the Boston Criteria version 2.0. This differs from secondary sICH, defined as hemorrhage due to vascular malformation, coagulopathy, trauma, malignancy, or reversible vasculopathy. Before hospital discharge, participants will receive baseline cognitive testing, MRI brain, and suPAR (soluble urokinase-type plasminogen activator receptor) serology sampling. After discharge from the hospital, participants will follow up in RUMC's Comprehensive Stroke Clinic at 3 months as part of their routine stroke care per our center's protocol. At the 3-month visit, participants will receive cognitive testing and provide suPAR serology. Participants will complete an interim 6-month visit with cognitive testing and suPAR serology. At a 12-month research clinic visit, participants will repeat cognitive testing, brain MRI, and suPAR serology. All participant encounters will provide the opportunity to gather interim clinical data such as new medical diagnoses or repeat hospitalizations.
- Conditions
- Primary Intracerebral Hemorrhage
- Being tested
- MRI, Blood Draw, Cognitive Test
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRIDiagnostic test
MRI during hospitalization and at 12 months post sICH
Blood DrawDiagnostic test
Will occur during hospitalization and at 3, 6 and 12 months post sICH
Cognitive TestDiagnostic test
Cognitive testing will occur during hospitalization and at 3, 6 and 12 months post sICH
What is being measured
The primary outcome is the main question the study is designed to answer.
Global Cognition
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
Measured: From date of randomization and assessed throughout the during hospitalization for qualifying ICH event up to 12 months
Global Cognition
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
Measured: 3 months after hospitalization
Global Cognition
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
Measured: 6 months after hospitalization
Global Cognition
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
Measured: 12 months after hospitalization
Absolute volumetric change in White Matter Hyperintensity (WMH)
Uses a novel imaging analysis algorithm on serial 3-Tesla brain MRI
Measured: from MRI at hospitalization to MRI at 12 months
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative groups
Measured: From date of consent and assessed during hospitalization for qualifying ICH event up to 12 months
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative
Measured: 3 months after hospital discharge
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative
Measured: 6 months after hospital discharge
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative
Measured: 12 months after hospital discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2025
- Study start2 Aug 2025
- Primary completion1 Aug 2029 (estimated)
- Study completion1 Aug 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (52)Papers the sponsor has linked to this study.
- Other trials for Primary Intracerebral HemorrhageStudies of the same condition, open and under way.
- More trials run by Rush University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 118 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Rush University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Rajeev Garg, MD, Principal investigator, Rush University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06836141
- Sponsor's protocol ID
- 23022401
- Other IDs
- 1R01NS135614-01A1
- Status last verified
- Jul 2026
- First submitted
- 15 Jan 2025
- Last updated
- 13 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, Hemphill JC 3rd, Johnson R, Keigher KM, Mack WJ, Mocco J, Newton EJ, Ruff IM, Sansing LH, Schulman S, Selim MH, Sheth KN, Sprigg N, Sunnerhagen KS; American Heart Association/American Stroke Association. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022 Jul;53(7):e282-e361. doi: 10.1161/STR.0000000000000407. Epub 2022 May 17. No abstract available.
PubMed 35579034Hemorrhagic Stroke Academia Industry (HEADS) Roundtable Participants; Second HEADS Roundtable Participants. Recommendations for Clinical Trials in ICH: The Second Hemorrhagic Stroke Academia Industry Roundtable. Stroke. 2020 Apr;51(4):1333-1338. doi: 10.1161/STROKEAHA.119.027882. Epub 2020 Feb 10. No abstract available.
PubMed 32078490Hwang DY, Kim KS, Muehlschlegel S, Wartenberg KE, Rajajee V, Alexander SA, Busl KM, Creutzfeldt CJ, Fontaine GV, Hocker SE, Madzar D, Mahanes D, Mainali S, Sakowitz OW, Varelas PN, Weimar C, Westermaier T, Meixensberger J. Guidelines for Neuroprognostication in Critically Ill Adults with Intracerebral Hemorrhage. Neurocrit Care. 2024 Apr;40(2):395-414. doi: 10.1007/s12028-023-01854-7. Epub 2023 Nov 3.
PubMed 37923968Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36. doi: 10.1038/nrm2821.
PubMed 20027185Nikorowitsch J, Borchardt T, Appelbaum S, Ojeda F, Lackner KJ, Schnabel RB, Blankenberg S, Zeller T, Karakas M. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function. J Am Heart Assoc. 2020 Apr 21;9(8):e015452. doi: 10.1161/JAHA.119.015452. Epub 2020 Apr 17.
PubMed 32299288Wilson RS, Yu L, Lamar M, Schneider JA, Boyle PA, Bennett DA. Education and cognitive reserve in old age. Neurology. 2019 Mar 5;92(10):e1041-e1050. doi: 10.1212/WNL.0000000000007036. Epub 2019 Feb 6.
PubMed 30728309Garg RK, Khan J, Dawe RJ, Conners J, John S, Prabhakaran S, Kocak M, Bhabad S, Simpson SL, Ouyang B, Jhaveri M, Bleck TP. The Influence of Diffusion Weighted Imaging Lesions on Outcomes in Patients with Acute Spontaneous Intracerebral Hemorrhage. Neurocrit Care. 2020 Oct;33(2):552-564. doi: 10.1007/s12028-020-00933-3.
PubMed 32072457Grosu S, Rospleszcz S, Hartmann F, Habes M, Bamberg F, Schlett CL, Galie F, Lorbeer R, Auweter S, Selder S, Buelow R, Heier M, Rathmann W, Mueller-Peltzer K, Ladwig KH, Grabe HJ, Peters A, Ertl-Wagner BB, Stoecklein S. Associated factors of white matter hyperintensity volume: a machine-learning approach. Sci Rep. 2021 Jan 27;11(1):2325. doi: 10.1038/s41598-021-81883-4.
PubMed 33504924Greenberg SM, O'Donnell HC, Schaefer PW, Kraft E. MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology. 1999 Sep 22;53(5):1135-8. doi: 10.1212/wnl.53.5.1135.
PubMed 10496283Maclullich AM, Wardlaw JM, Ferguson KJ, Starr JM, Seckl JR, Deary IJ. Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1519-23. doi: 10.1136/jnnp.2003.030858.
PubMed 15489380Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.
PubMed 19414839Chew-Harris J, Appleby S, Richards AM, Troughton RW, Pemberton CJ. Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals. Clin Biochem. 2019 Jul;69:36-44. doi: 10.1016/j.clinbiochem.2019.05.010. Epub 2019 May 23.
PubMed 31129182Eugen-Olsen J, Ladelund S, Sorensen LT. Plasma suPAR is lowered by smoking cessation: a randomized controlled study. Eur J Clin Invest. 2016 Apr;46(4):305-11. doi: 10.1111/eci.12593. Epub 2016 Feb 19.
PubMed 26799247Haupt TH, Kallemose T, Ladelund S, Rasmussen LJ, Thorball CW, Andersen O, Pisinger C, Eugen-Olsen J. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insights. 2014 Dec 16;9:91-100. doi: 10.4137/BMI.S19876. eCollection 2014.
PubMed 25574132Mehta A, Desai SR, Ko YA, Liu C, Dhindsa DS, Nayak A, Hooda A, Martini MA, Ejaz K, Sperling LS, Reiser J, Hayek SS, Quyyumi AA. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease. J Am Heart Assoc. 2020 Mar 3;9(5):e015457. doi: 10.1161/JAHA.119.015457. Epub 2020 Feb 22.
PubMed 32089048
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Silent Brain Infarcts in Spontaneous Intracerebral Hemorrhage as a Prognostic Biomarker for Vascular Contributions to Cognitive Impairment and Dementia (VCID)
- ClinicalTrials.gov ID
- NCT06836141
- Acronym / sponsor ID
- 23022401
- Conditions
- Primary Intracerebral Hemorrhage
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 118 participants (estimated)
- Lead sponsor
- Rush University Medical CenterUniversity, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- Study start
- 2 Aug 2025 (actual)
- Primary completion
- 1 Aug 2029 (estimated)
- Study completion
- 1 Aug 2029 (estimated)
- First posted
- 20 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to see if silent brain infarcts (SBIs), or stroke-like symptoms detectable during brain imaging, are a possible contributor to cognitive decline for patients diagnosed with spontaneous intracerebral hemorrhage (sICH), or blood clot in the brain. The main questions it aims to answer are
- if SBIs in sICH are associated with a lower cognitive level and more rapid cognitive decline
- if SBIs in sICH are associated with certain findings on brain imaging
- if SBIs in sICH are associated with higher inflammation measured by certain blood tests
Participants will undergo
- cognitive testing during hospitalization, and at 3, 6 and 12 months after the sICH
- Magnetic Resonance Imaging (MRI) of the brain during hospitalization and 12 months after the sICH
- blood draws during hospitalization and at 3, 6 and 12 months after the sICH
Detailed description
This proposal's objective is to establish SBIs (silent brain infarct) as an early, pathophysiologically plausible neuroimaging biomarker for VCID (vascular contributions to cognitive impairment and dementia) in sICH (spontaneous intracerebral hemorrhage) patients. To attain the overall objective, we will recruit a cohort of 118 sICH participants over 3 years and longitudinally measure cognitive function, WMH volumetric progression, and serum suPAR levels. Aim #1: To test the hypothesis that SBIs in sICH are associated with a lower cognitive level and more rapid cognitive decline. Approach: In sICH patients with and without SBIs, we will compare global cognition (primary analysis) and multiple cognitive domains (secondary analysis) at hospitalization, and at 3 months, 6 months, and 12 months after discharge using a comprehensive cognitive battery. Aim #2: To test the hypothesis that SBIs in sICH are associated with more rapid WMH (white matter hyperintensities) progression as measured by serial MRI (magnetic resonance imaging). Approach: In sICH patients with and without SBIs, we will compare the absolute volumetric change in WMH using a novel imaging analysis algorithm on serial 3-Tesla brain MRI at hospitalization and at 12 months after discharge. Aim #3: To test the hypothesis that SBIs in sICH are associated with higher chronic systemic inflammation as measured by serum suPAR. Approach: In sICH patients with and without SBIs, we will compare serum levels of suPAR at hospitalization, and at 3 months, 6 months, and 12 months after discharge.
This study will be a prospective longitudinal study of sICH patients comparing those with and without SBIs. All patients with primary sICH are admitted to Rush University Medical Center's (RUMC) Neurosciences Intensive Care Unit and managed by a multi-disciplinary team of neurologists and neurosurgeons according to a standardized protocol based on current guidelines. Primary sICH will be defined as either hypertensive or related to cerebral amyloid angiopathy as diagnosed using the Boston Criteria version 2.0. This differs from secondary sICH, defined as hemorrhage due to vascular malformation, coagulopathy, trauma, malignancy, or reversible vasculopathy. Before hospital discharge, participants will receive baseline cognitive testing, MRI brain, and suPAR (soluble urokinase-type plasminogen activator receptor) serology sampling. After discharge from the hospital, participants will follow up in RUMC's Comprehensive Stroke Clinic at 3 months as part of their routine stroke care per our center's protocol. At the 3-month visit, participants will receive cognitive testing and provide suPAR serology. Participants will complete an interim 6-month visit with cognitive testing and suPAR serology. At a 12-month research clinic visit, participants will repeat cognitive testing, brain MRI, and suPAR serology. All participant encounters will provide the opportunity to gather interim clinical data such as new medical diagnoses or repeat hospitalizations.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients admitted to Rush University Medical Center with an intracerebral hemorrhage.
Key inclusion criteria (2 listed)
- Primary Intracerebral Hemorrhage
- Age ≥ 18 and < 80 years
Key exclusion criteria (1 listed)
- Pre-existing dementia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRIMRI during hospitalization and at 12 months post sICH | Diagnostic test | – |
| Blood DrawWill occur during hospitalization and at 3, 6 and 12 months post sICH | Diagnostic test | – |
| Cognitive TestCognitive testing will occur during hospitalization and at 3, 6 and 12 months post sICH | Diagnostic test | – |
Primary outcome
Global Cognition
Time frame: From date of randomization and assessed throughout the during hospitalization for qualifying ICH event up to 12 months
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
Global Cognition
Time frame: 3 months after hospitalization
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
Global Cognition
Time frame: 6 months after hospitalization
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
Global Cognition
Time frame: 12 months after hospitalization
Assessed via the the Late Onset Alzheimer's Disease Family Study Cognitive Battery
Absolute volumetric change in White Matter Hyperintensity (WMH)
Time frame: from MRI at hospitalization to MRI at 12 months
Uses a novel imaging analysis algorithm on serial 3-Tesla brain MRI
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
Time frame: From date of consent and assessed during hospitalization for qualifying ICH event up to 12 months
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative groups
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
Time frame: 3 months after hospital discharge
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
Time frame: 6 months after hospital discharge
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative
Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels
Time frame: 12 months after hospital discharge
compare SuPAR levels between the silent brain infarct (SBI) positive and the SBI negative
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- Background: PubMed 35579034Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, Hemphill JC 3rd, Johnson R, Keigher KM, Mack WJ, Mocco J, Newton EJ, Ruff IM, Sansing LH, Schulman S, Selim MH, Sheth KN, Sprigg N, Sunnerhagen KS; American Heart Association/American Stroke Association. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022 Jul;53(7):e282-e361. doi: 10.1161/STR.0000000000000407. Epub 2022 May 17. No abstract available.
- Background: PubMed 32078490Hemorrhagic Stroke Academia Industry (HEADS) Roundtable Participants; Second HEADS Roundtable Participants. Recommendations for Clinical Trials in ICH: The Second Hemorrhagic Stroke Academia Industry Roundtable. Stroke. 2020 Apr;51(4):1333-1338. doi: 10.1161/STROKEAHA.119.027882. Epub 2020 Feb 10. No abstract available.
- Background: PubMed 37923968Hwang DY, Kim KS, Muehlschlegel S, Wartenberg KE, Rajajee V, Alexander SA, Busl KM, Creutzfeldt CJ, Fontaine GV, Hocker SE, Madzar D, Mahanes D, Mainali S, Sakowitz OW, Varelas PN, Weimar C, Westermaier T, Meixensberger J. Guidelines for Neuroprognostication in Critically Ill Adults with Intracerebral Hemorrhage. Neurocrit Care. 2024 Apr;40(2):395-414. doi: 10.1007/s12028-023-01854-7. Epub 2023 Nov 3.
- Background: PubMed 20027185Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36. doi: 10.1038/nrm2821.
- Background: PubMed 32299288Nikorowitsch J, Borchardt T, Appelbaum S, Ojeda F, Lackner KJ, Schnabel RB, Blankenberg S, Zeller T, Karakas M. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function. J Am Heart Assoc. 2020 Apr 21;9(8):e015452. doi: 10.1161/JAHA.119.015452. Epub 2020 Apr 17.
- Background: PubMed 30728309Wilson RS, Yu L, Lamar M, Schneider JA, Boyle PA, Bennett DA. Education and cognitive reserve in old age. Neurology. 2019 Mar 5;92(10):e1041-e1050. doi: 10.1212/WNL.0000000000007036. Epub 2019 Feb 6.
- Background: PubMed 32072457Garg RK, Khan J, Dawe RJ, Conners J, John S, Prabhakaran S, Kocak M, Bhabad S, Simpson SL, Ouyang B, Jhaveri M, Bleck TP. The Influence of Diffusion Weighted Imaging Lesions on Outcomes in Patients with Acute Spontaneous Intracerebral Hemorrhage. Neurocrit Care. 2020 Oct;33(2):552-564. doi: 10.1007/s12028-020-00933-3.
- Background: PubMed 33504924Grosu S, Rospleszcz S, Hartmann F, Habes M, Bamberg F, Schlett CL, Galie F, Lorbeer R, Auweter S, Selder S, Buelow R, Heier M, Rathmann W, Mueller-Peltzer K, Ladwig KH, Grabe HJ, Peters A, Ertl-Wagner BB, Stoecklein S. Associated factors of white matter hyperintensity volume: a machine-learning approach. Sci Rep. 2021 Jan 27;11(1):2325. doi: 10.1038/s41598-021-81883-4.
- Background: PubMed 10496283Greenberg SM, O'Donnell HC, Schaefer PW, Kraft E. MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology. 1999 Sep 22;53(5):1135-8. doi: 10.1212/wnl.53.5.1135.
- Background: PubMed 15489380Maclullich AM, Wardlaw JM, Ferguson KJ, Starr JM, Seckl JR, Deary IJ. Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1519-23. doi: 10.1136/jnnp.2003.030858.
- Background: PubMed 19414839Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.
- Background: PubMed 31129182Chew-Harris J, Appleby S, Richards AM, Troughton RW, Pemberton CJ. Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals. Clin Biochem. 2019 Jul;69:36-44. doi: 10.1016/j.clinbiochem.2019.05.010. Epub 2019 May 23.
- Individual participant dataSharing planned: No
Related trials for Primary Intracerebral Hemorrhage
Recruiting
Neurologic Stem Cell Treatment Study
Neurologic Disorders, Nervous System Diseases
Not yet recruitingPhase 2
GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial
Intracerebral Hemorrhage
Active, not recruitingObservational study
Quality Improvement Initiative for Enhancing Early Mobilization in Intracerebral Hemorrhage Patients
Primary Intracerebral Hemorrhage, Early Mobilization
Recruiting
Statins for Treatment of Primary Intracerebral Hemorrhage
Cerebrovascular Disorders, Intracranial Hemorrhages
Not yet recruitingPhase 4
Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial
Intracerebral Hemorrhage, Hemorrhagic Stroke, Intracerebral
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Rajeev Garg, MD contact
Rajeev Garg, MD principal investigator
Rush University Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Primary Intracerebral Hemorrhage, run by Rush University Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amanda Sremac, BS (312-942-0593, Amanda_C_Sremac@rush.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Global Cognition (time frame: From date of randomization and assessed throughout the during hospitalization for qualifying ICH event up to 12 months). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06836141, which also lists 52 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.